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Background There is a paucity of data on the national
population-level effectiveness of preventing mother-to-
child transmission (PMTCT) programmes in high-HIV-
prevalence, resource-limited settings. We assessed
national PMTCT impact in South Africa (SA), 2010.
Methods A facility-based survey was conducted using
a stratified multistage, cluster sampling design. A
nationally representative sample of 10 178 infants aged
4–8 weeks was recruited from 565 clinics. Data
collection included caregiver interviews, record reviews
and infant dried blood spots to identify HIV-exposed
infants (HEI) and HIV-infected infants. During analysis,
self-reported antiretroviral (ARV) use was categorised:
1a: triple ARV treatment; 1b: azidothymidine
>10 weeks; 2a: azidothymidine ≤10 weeks; 2b:
incomplete ARV prophylaxis; 3a: no antenatal ARV and
3b: missing ARV information. Findings were adjusted for
non-response, survey design and weighted for live-birth
distributions.
Results Nationally, 32% of live infants were HEI; early
mother-to-child transmission (MTCT) was 3.5% (95% CI
2.9% to 4.1%). In total 29.4% HEI were born to
mothers on triple ARV treatment (category 1a) 55.6%
on prophylaxis (1b, 2a, 2b), 9.5% received no antenatal
ARV (3a) and 5.5% had missing ARV information (3b).
Controlling for other factors groups, 1b and 2a had
similar MTCT to 1a (Ref; adjusted OR (AOR) for 1b,
0.98, 0.52 to 1.83; and 2a, 1.31, 0.69 to 2.48). MTCT
was higher in group 2b (AOR 3.68, 1.69 to 7.97).
Within group 3a, early MTCT was highest among
breastfeeding mothers 11.50% (4.67% to 18.33%) for
exclusive breast feeding, 11.90% (7.45% to 16.35%)
for mixed breast feeding, and 3.45% (0.53% to 6.35%)
for no breast feeding). Antiretroviral therapy or
>10 weeks prophylaxis negated this difference (MTCT
3.94%, 1.98% to 5.90%; 2.07%, 0.55% to 3.60%
and 2.11%, 1.28% to 2.95%, respectively).
Conclusions SA, a high-HIV-prevalence middle income
country achieved <5% MTCT by 4–8 weeks post
partum. The long-term impact on PMTCT on HIV-free
survival needs urgent assessment.
INTRODUCTION
Eliminating mother-to-child transmission (MTCT)
of HIV is a global public health priority.1
Randomised clinical trials in the USA, Europe and
Asia show that antenatal antiretroviral (ARV)
interventions reduce the risk of MTCT from 15%
to 30% during pregnancy and labour to <2% in
non-breastfeeding populations and <5% in breast-
feeding populations.2 3 There is a paucity of data
on the national (countrywide) population-level
effectiveness of recent programmes to prevent
MTCT (PMTCT) in high-HIV-prevalence countries
such as South Africa (SA), and no consensus meth-
odology for such evaluations.4 Previous research
evaluating PMTCT impact in routine settings have
been mainly conducted in the era of single-dose
nevirapine5–10 (NVP) in confined settings5–13—
except for the Zambian component of the PEARL
study13—or in well-resourced settings.14 As far as
we know, the Zambian PEARL results have not yet
been reported. Thus country-level PMTCT impact
in resource-limited, high-HIV-prevalence settings
cannot be extrapolated or assumed from previous
studies.
We conducted a survey to assess the early
population-level effectiveness of SA’s PMTCT pro-
gramme, using vertical HIV transmission between 4
and 8 weeks post partum as the main outcome of
interest. The survey started 1 month after SA




A national facility-based evaluation using a stratified
multistage probability proportional to size (PPS)
sampling design was conducted from June to
December 2010. A desired sample size of 12 200
infant dried blood spot (iDBS) specimens was cal-
culated to measure a projected early MTCT risk of
6.6% with a precision of 1% and a design effect of
2 (see web appendix 2). The 12 200 specimens
were partitioned between the nine South African
provinces as follows: Eastern Cape 1400, Free State
1300, Gauteng 1800, Kwa-Zulu Natal 1400,
Limpopo 1400, Mpumalanga 1600, Northern
Cape 700, North West 1200 and Western Cape
1400. The facility sampling frame only included
public primary healthcare clinics/community health
centres (PHCs/CHCs) offering 6-week immunisa-
tion services and assumed population representa-
tiveness thereof for two reasons: (1) 6-weeks
immunisation coverage has been documented as
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99% (95% CI 98% to 99%)15 and (2) at least 85% of 6-week
immunisations are performed in public health facilities.16 We
stratified all PHC/CHC facilities into three strata per province
based on their 6-week immunisation patient load and their
2008 annual antenatal HIV prevalence. The 6-week immunisa-
tion load was obtained from the 2007 District Health
Information System (DHIS; see web appendix 3) and facilities
were categorised based on their mean annual 6-week immuni-
sations: ≥300 annual immunisations (busy facilities) with dis-
trict HIV prevalence at or more than the national average
(≥29%), busy facilities with district HIV prevalence <29%,
and 130–300 annual immunisations (medium-sized facilities).17
Facilities with a <130 annual immunisation load were
excluded from the sampling frame. On the basis of the DHIS
data, we calculated an estimated number of immunisations per
facility over a feasible 3-week recruitment period (4 weeks in
Northern Cape province) for each province. The number of
facilities needed per stratum and thus per province to achieve
the sample size of 12 200 was thus calculated as 580. These
580 facilities (34–79 facilities per province) were randomly
selected within each stratum in each of the nine provinces with
probability proportional to size (PPS).18 A fixed number of
caregiver/infant pairs were consecutively or systematically (in
facilities with queues of mothers waiting for immunisation)
selected from facilities over a planned recruitment window.
Systematic sampling was conducted after determining the
recruitment interval based on the sample size needed for that
day and starting the selection with a randomly selected patient
folder or mother. Data collectors (study nurses) were trained
on sampling methods using standardised operating procedures.
Infants aged 4–8 completed weeks, receiving their 6-week
immunisation, whose caregivers provided informed consent
were eligible to participate.
Data collection procedures
Trained study nurses conducted face-to-face interviews. Mode of
delivery, gestational age at delivery, and infant birth weight were
documented from each infant’s patient-held health chart.19
Self-reported data on maternal HIV testing, maternal CD4 test
uptake/results, maternal ARV regimens, maternal antenatal care
(ANC) and infant feeding practices (recall of previous 8 days) were
gathered. Data on maternal ARV regimens were documented after
showing mothers pictures of ARVs, and samples where available.
No data were collected on exact drug regimens in women on anti-
retroviral therapy (ART), drug dosages, duration of ARTand com-
pliance. Data were collected using hand-held devices (cellphones)
and interview data were uploaded real-time into a web-based
database.20
Pretest counselling was conducted and iDBS were obtained
from heel prick blood draw onto Munktell-TFN 5-spot paper.
Infant HIV testing, using iDBS at 6 weeks post partum has been
the standard of care in South Africa since 2005. As study nurses
were drawing blood from all consented infants regardless of
PMTCT or HIV exposure, iDBS were processed for HIV expos-
ure and infection (see section below). Study nurses or routine
national systems returned test results to facilities. Study nurses
trained Department of Health nurses on the interpretation of
study results and the latter returned test results to participants.
Anonymised results were captured in the study database.
Mothers and infants were referred into routine HIV-related care
and treatment services as needed. No maternal blood was
drawn.
Laboratory testing and definitions
All iDBS samples were tested in one accredited laboratory at the
National Institute for Communicable Diseases, National Health
Laboratory Services, Johannesburg, using standardised accre-
dited procedures. iDBS underwent serology testing for HIV anti-
body using an enzyme immunoassay (EIA; Genscreen HIV1/2
Ab EIAV.2, Bio-Rad Laboratories, France). All antibody-positive
and 10% of negative iDBS specimens were retested using a
second EIA (Vironostika HIV Uni-form II plus O, bioMēr̀ieux
Clinical Diagnostics, Marcy-L’Etoile, France). Discordant results
(discordance between mother’s reported HIV status and infant
EIA result or discordance between the first and second EIA
results) were checked using Western blot (GS HIV-1, Bio-Rad
France). iDBS with concordant positive or discordant EIA
results or from self-reporting HIV-positive mothers were tested
using a qualitative DNA PCR to determine the infant’s HIV
infection (COBAS AmpliPrep/COBAS TaqMan—CAP/CTM—
Qualitative assay V.1.0 assay, Roche Diagnostics, Branchburg,
New Jersey, USA). Confirmed antibody-positive iDBS specimens
indicated infant HIV exposure (HIV-exposed infant (HEI)). EIA
and PCR positive iDBS were defined as confirmed early HIV
infection.
Statistical methods
Using information from the sampling design and SA’s 2010 live-
birth distribution across provinces, the survey sample was
weighted to account for sample ascertainment due to non-
response (refusal), undersampling (related to clinic immunisa-
tion uptake), lost and poor quality iDBS specimens within each
facility, as well as the disproportionate sampling of provinces.
Analysis procedures thus accounted for the stratified cluster
survey design and were weighted for non-response.21–23 All stat-
istical analyses were carried out using SAS (V.9.2, SAS Institute,
Cary, North Carolina, USA). Weighted point estimates of trans-
mission risks were estimated at national and provincial levels,
and for six treatment subgroups (created during analysis and
defined below) with 95% CIs using standard bivariate analyses
appropriate for the sample design. All multivariate analyses used
sample survey procedures to conduct logistic regression with
both the complete case data and a full-imputed data set.21 24
This multivariate logistic regression analysis was used to assess
the association between key interventions and behaviours and
MTCT.
We categorised maternal self-reported ARV uptake into three
main groups, with two subcategories in each group (figure 1):
We also considered two other MTCT interventions: vaginal
versus caesarean delivery and infant feeding practice, which was
categorised into no breast feeding (NBF), exclusive breast
feeding (EBF) or mixed breast feeding (MBF), as a measure of
breast milk exposure. Several factors including sociodemo-
graphic (education, socioeconomic status) and pregnancy-related
factors (gestational age at first antenatal visit, pregnancy
planned or not, reported maternal CD4 cell count, infant birth
weight and parity) were considered potential confounders of the
measured effect of these interventions. The socioeconomic
status variable was constructed using a clustering algorithm that
considered 10 interview items (see web appendix 4).25 26
Self-reported gestational age at first ANC and CD4 cell count
was missing for approximately 16.5% and 44% of the popula-
tion, respectively, as a result of poor documentation or mothers
not being told or not remembering their CD4 cell count.
Multiple imputations were used to calculate gestational age for
participants with missing values and were also considered for
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CD4 cell count (see web appendix 5).24 Imputed CD4 cell
count was not used in the final multivariate analysis due to the
large number of missing values. With the exception of mother’s
age, all potential confounding factors were included in multi-
variate analyses as categorical variables. Interactions between the
ARV regimen and breast feeding were considered a priori as
these were two main exposures of interest. Confounding
assessment was conducted on the full model which included all
potential confounders and this interaction effect. Variables
that changed the effect of either exposure variable by more
than 10% were considered as likely confounders in these
data.27 The model including all potential confounders did
not change estimates of the relative odds of MTCT by
>10% (compared with Model 1, table 3), but the
Figure 1 Categorisation of self-reported antiretroviral uptake (ARV, antiretroviral; ARVP, ARV prophylaxis; wks, weeks).
Figure 2 Eligibility and participation in the 2010 South African PMTCT survey: unweighted numbers (DBS, dried blood spot; PMTCT, preventing
mother-to-child transmission).
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interaction between the ARV and breast feeding exposure
variables was significant in the logistic regression models.
Therefore, to simplify interpretation, we report an inter-
action between our exposures by creating variables
representing the possible two-way combinations of our
exposures and then estimating the proportion of exposed
infants with evidence of transmission in each strata without
adjustment for other factors.28–30





Maternal characteristics Weighted% 95% CI Weighted% 95% CI
Mother 96.8 96.2 to 97.2 96.9 96.3 to 97.5
Other caregiver 3.2 2.8 to 3.8 3.1 2.5 to 3.7
Maternal age mean (range) 25.9 (13 to 49) 27.7 (15 to 46)
Married status*
Single 72.6 70.8 to 74.4 78.4 76.4 to 80.5
Married/cohabiting 27.1 25.3 to 28.8 20.2 18.2 to 22.2
Widow/divorced 0.2 0.1 to 0.3 0.8 0.5 to 12
No information 0.1 0.03 to 0.2 0.6 0.3 to 0.8
Education level*
None 2.0 1.3 to 2.0 2.6 2.0 to 3.2
Grade 1–7 13.4 12.4 to 14.4 18.2 16.7 to 19.8
Grade 8–12 77.8 76.7 to 79.3 75.6 73.8 to 77.5
Grade 12+ 6.5 5.7 to 7.3 2.7 2.1 to 3.4
Missing 0.4 0.3 to 0.6 0.8 0.5 to 1.1
SES*
Average† 70.5 68.5 to 72.6 64.3 61.6 to 67.0
Lower 14.5 12.7 to 16.2 23.1 20.5 to 25.7
Lowest 15.0 13.7 to 16.4 12.6 11.1 to 14.1
Parity*
1 41.9 40.6 to 43.2 21.5 19.8 to 23.2
2 28.6 27.5 to 29.8 36.6 34.7 to 38.5
≥3 26.8 25.6 to 28.0 39.5 37.7 to 41.3
Missing 2.6 2.2 to 3.0 2.4 1.9 to 2.8
Number of live children*
1 45.1 43.7 to 46.4 27.2 25.4 to 28.9
2 28.4 27.9 to 29.4 37.5 35.7 to 39.3
≥3 23.9 22.8 to 25.1 33.0 31.2 to 34.7
Missing 2.6 2.2 to 3.0 2.4 1.9 to 2.8
Planned pregnancy*
Yes 39.7 38.1 to 41.3 35.5 33.3 to 37.8
No 57.2 55.6 to 56.9 61.4 59.1 to 63.6
Missing 3.1 2.6 to 3.5 3.1 2.5 to 3.7
Number of ANC visits
Had 1 ANC 96.5 96.0 to 97.0 96.4 95.8 to 96.9
Had <1 ANC 3.5 3.2 to 4.0 3.6 3.1 to 4.2
Gestational age of first ANC visit (weeks)
≤12 23.2 22.0 to 24.4 20.0 18.3 to 21.7
13–16 13.5 12.5 to 14.6 13.6 12.3 to 14.9
17–20 19.1 18.0 to 20.2 18.9 17.1 to 20.7
21–24 14.9 13.8 to 15.9 17.6 16.0 to 19.4
25–28 9.3 8.3 to 10.2 9.3 8.1 to 10.5
29–32 2.2 1.8 to 2.5 2.0 1.5 to 2.4
33–36 0.6 0.4 to 0.8 0.7 0.4 to 1.0
37+ 0.7 0.5 to 0.9 0.9 0.5 to 1.2
Missing 16.5 14.7 to 18.4 17.0 14.7 to 19.3
Infant characteristics
Infant sex (male) 51.2 50.0 to 52.4 49.1 47.1 to 51.1
Infant’s birth weight*
<2.5 kg 11.4 10.4 to 12.4 13.4 12.1 to 14.7
≥2.5 kg 88.6 87.6 to 89.6 86.6 85.3 to 87.9
*p<0.05 (Rao-Scott χ2 test) Nw=weighted population number.
†‘Average’ SES in this population would be low compared with SES of groups using private healthcare or living in ‘developed’ countries.
ANC, antenatal care; SES, socioeconomic status.
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RESULTS
Description of study population
A total of 10 178 caregiver–infant pairs (83.4% of the desired
sample size) with eligible iDBS samples from 565 facilities were
analysed (figure 2).
Sample ascertainment was affected by the availability of
immunisation services at PHC facilities, poor weather and
funding constraints. Sociodemographic data from the screening
questionnaire showed that there were no statistically significant
differences between 662 pairs who either refused participation
in the study or refused iDBS and those included. Considering
the sampling design and weighting, these 10 178 infants
(median age 39 days, Q1-3 37–41 days) represented the esti-
mated 1 287 854 live births in SA during 2010.
Overall, most infants were born to mothers who described
themselves as single (unmarried and non-cohabiting; 74.5%),
completed 8 years of schooling (77.2%), and had their first
antenatal visit ≤28 weeks of pregnancy (79.8%); 98.8%
(98.5–99.0%) had been tested for HIV and 98.6%
(98.4–98.9%) had received their result. Most (68.5%) infants
lived in households with an average socioeconomic status, were
born at ≥2.5 kg (88%), had ≥1 sibling (60.7%), and almost all
(96.8%) were accompanied by their mothers. Of these, 29.4%
self-reported being HIV-infected; 78% of HIV-infected mothers
reported CD4 cell count testing and 43% knew their result; of
these, 62% reported a CD4 cell count ≤350 cells/mL.
Almost one-third (32.0% (95% CI 30.4% to 33.3%)) of
sampled infants were HEI. This varied by province (see web
appendix 6, table 15). HEI were significantly more likely to be
born with low birth weight, from an unplanned pregnancy to a
single mother with less education, lower socioeconomic status and
higher parity, compared with HIV-unexposed infants (table 1).
Among HEI (n=3107), at least 85% were born to mothers
who reported receiving some ARVs antenatally, including 29.4%
on ART (group 1a, figure 1) and 55.6% on ARV prophylaxis
(ARVP). The latter included 27.8% on ARVP >10 weeks (group
1b), 22.8% on ARVP ≤10 weeks (group 2a) and 5% on incom-
plete ARVP (group 2b); 9.5% of mothers with HEI reported
not receiving ARVs (group 3a) and 5.5% had missing ARV
information. With regard to postnatal prophylaxis, 80% of all
HEI received either NVP or azidothymidine (AZT) at birth,
including 96% of infants born to women on ART. In total, 34%
HEI were on NVP when interviewed. Among HEI, 61.5%
(95% CI 59.2% to 63.8%) reportedly received formula feeding
(no breast milk), 20.4% (95% CI 18.5% to 22.3%) EBF, and
18.1% (95% CI 16.5% to 19.7%) MBF.
Weighted population-level risk of early (4–8 weeks) MTCT
The national cumulative risk of early MTCT measured at 4–
8 weeks post partum was 3.5% (95% CI 2.9% to 4.1%), based
on 125 HIV transmissions. This varied by province (see web
appendix 6, table 15). The determinants of these provincial var-
iations will be presented and discussed in another manuscript.
The unadjusted risk of early MTCT was similar whether
mothers received ART (group 1a, figure 3—2.1%, 95% CI 1.2%
to 3.0%), ARVP >10 weeks (group 1b—2.2%, 95% CI 1.2% to
3.0%), or ARVP ≤10 weeks (group 2a—3.0%, 95% CI 1.9% to
4.0%). Mothers who reportedly received incomplete ARVP
(group 2b—8.4%, 95% CI 4.0% to 12.7%) or no ARVs (group 3a
—9.0%, 95% CI 6.4% to 11.5%) were significantly more likely to
transmit HIV to their infants than mothers in the other three ARV
categories (figure 3).
Models adjusted for sociodemographic and pregnancy-related
factors did not result in meaningful differences (>10% change)
in the relative odds of early MTCT (table 2). There was no statis-
tically significant difference in the odds of MTCT between
mothers receiving ART (group 1a, figure 1, reference—adjusted
OR (AOR)=1) and those receiving either ARVP >10 weeks
(group 1b—AOR 0.98, 95% CI 0.52 to 1.83)) or ARVP
≤10 weeks (group 2a—AOR 1.31, 95% CI 0.69 to 2.48)).
However, early MTCTwas almost four times (AOR 3.68, 95%
CI 1.69 to 7.97) as high when ARVP was incomplete (group 2b),
compared with ART. Controlling for other factors including ARV,
early transmission was almost twice as high among mothers prac-
tising EBF (AOR 1.79, 95% CI 1.09 to 2.92) or MBF (AOR
1.70, 95% CI 1.09 to 2.67), compared with NBF (table 2).
Mode of delivery did not significantly vary the adjusted odds of
early MTCT.
Table 3 shows how the proportion of children who were HIV
infected by 4–8 weeks post partum varied by ARV regimen and
breast feeding practice. MTCT was significantly high among
breastfeeding mothers with no ARV exposure (11.50%, 95% CI
4.67% to 18.33% for EBF and 11.90%, 95% CI 7.45% to
16.35% for MBF, compared with NBF 3.45%, 95% CI 0.53%
to 6.37%). However, maternal ART or ARVP >10 weeks
(advanced regimens) significantly reduced early MTCT among
breastfeeding mothers (3.94%, 95% CI 1.98% to 5.90% for
EBF, 2.07%, 95% CI 0.55% to 3.60% for MBF) whose early
MTCT was similar to non-breastfeeding mothers on advanced
regimens (2.11%, 95% CI 1.28% to 2.95%). Early MTCT rates
were similar across levels of ARV exposure for both birth weight
and mode of delivery, suggesting no interaction between ARV
use and these factors.
DISCUSSION
Our data show that in SA, a high-HIV-prevalence setting with
the largest population of HIV-infected pregnant women,31
PMTCT programming was able to reduce early MTCT nation-
ally to 3.5% (95% CI 2.9% to 4.1%). Assuming 1.2 million live
births/year in SA and previously estimated 25% transmission in
the absence of ARV interventions, these results estimate an 86%
reduction in early MTCTwith an estimated 82 560 early infant
HIV infections averted annually. These results were achieved
with maternal self-reported 29.4% ART coverage, 55.6% ARVP
coverage, 34% infant NVP coverage until interview, and 38.5%
prevalence of breast feeding. In exclusively or mixed breastfed
infants, maternal ART or ARVP >10 weeks or ARVP ≤10 weeks
or incomplete ARVP significantly reduced MTCT compared
with no known ARV (group 3, figure 1).
These results are noteworthy as they closely reflect a country-
wide African context: although the survey was conducted in
only 17% of primary healthcare facilities, we targeted immun-
isation services where >85% infants nationally received care,
included all eligible infants aged 4–8 weeks regardless of their
HIV and PMTCT programme exposure and selected facilities
randomly after a multistage PPS sampling methodology.
Sampling included stratification by antenatal HIV prevalence
and results were weighted for sample ascertainment and popula-
tion live births. This made it possible for us to provide results
that closely approximate provincial and national countrywide
HIV prevalence and MTCT. The data show coherence between
self-reported maternal HIV seropositivity and 2009 antenatal
seroprevalence (29.4% and 29.3%, respectively), further illus-
trating the validity of our estimates.32 Our limitations could
have biased the results towards underestimating early MTCT:
we excluded small facilities from the sampling frame (7% total
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facilities), but have no evidence to believe that MTCT is higher
in these facilities; we excluded early infant deaths before
4–8 weeks post partum (150–290 infants die annually by
4 weeks of age in SA33) and there is currently no information
about their HIV exposure or infection status; and we also
excluded infants with poor access to care who receive their
6 weeks immunisation after 8 weeks post partum (who represent
15–20% of the population eligible for 6 week immunisa-
tions).15 16 The latter two limitations could have underestimated
MTCT risk and overestimated the absolute number of HIV
infections averted and ARV coverage. Furthermore, the use of a
single PCR test for infant diagnosis in populations with 4 weeks
or more of ART/ARVP use could have reduced test sensitivity to
86.2–99%, resulting in biases in diagnosis,34 35 and underesti-
mating the MTCT point estimate. However, it is quite likely
that the adjusted MTCT is still within the current 95% CI. It is
possible that mothers who reported no ARV exposure received
ARVs during labour (information bias) or were a healthy popu-
lation with good access to care and high CD4 cell counts
(selection bias) underestimating MTCT in the ‘no ARV’ group.
Accurate information on the exact PMTCT regimens, duration
of these regimens and adherence was not available, as our data
are self-reported and did not cover adherence. Thus, data on
MTCT by regimen or duration of ARTor ARVP should be inter-
preted cautiously as the direction of the biases (underestimating
or overestimating MTCT) cannot be predicted. In this manu-
script, we do not report on other factors that determine
PMTCT outcome, including the uptake of maternal HIV testing
and duration of ARV exposure. The former will be reported on
in another manuscript and the data on the latter are not avail-
able. Furthermore, we do not present data on facility-level/
health system factors that could affect MTCT, for example,
PMTCT quality, quality of facility infrastructure, patient satisfac-
tion and patients’ understanding of medication. These factors
were significantly associated with infant NVP coverage in the
PEARL study and may have helped us understand our data from
a health system perspective.36 Finally, our data are limited by
the lack of data on MTCT beyond 8 weeks post partum.
Figure 3 Weighted perinatal
mother-to-child transmission rate
measured at 4–8 weeks post partum
by ARV regimen, South Africa, 2010*
(ART, antiretroviral therapy; ARV,
antiretroviral; wks, weeks).























Mothers self-reported last CD4 cell count
≤350 839 19 1.67 (0.89 to 3.13) – – – –
>350 837 20 Ref. – – – –
Missing 1412 86 NA – – – –
ARV coverage during pregnancy§
Maternal ART (1a) 873 15 Ref. Ref. Ref.
ARVP >10 weeks (1b) 822 23 1.03 (0.56 to 1.90) 1.03 (0.54 to 1.99) 0.98 (0.52 to 1.83)
ARVP ≤10 weeks (2a) 710 28 1.42 (0.78 to 2.57) 1.45 (0.76 to 2.75) 1.31 (0.69 to 2.48)
Incomplete ARVP (2b) 163 13 4.24 (2.06 to 8.73) 3.95 (1.82 to 8.57) 3.68 (1.69 to 7.97)
No ARV (3a) 328 36 4.57 (2.63 to 7.95) 4.04 (2.14 to 7.62) 3.59 (1.94 to 6.66)
Missing ARV information (3b) 192 10 2.68 (1.21 to 5.90) 1.94 (0.66 to 5.75) 2.26 (0.89 to 5.73)
Feeding (8 days recall)
No breast milk 1870 50 Ref. Ref. Ref.
Exclusive breast feeding 618 32 1.82 (1.13 to 2.93) 1.86 (1.11 to 3.10) 1.79 (1.09 to 2.92)
Mixed breast milk 600 43 2.32 (1.54 to 3.51) 2.35 (1.49 to 3.71) 1.70 (1.09 to 2.67)
Delivery type
Caesarean 677 26 Ref.
Vaginal 2411 99 0.88 (0.57 to 1.38) 0.90 (0.56 to 1.47) 0.87 (0.53 to 1.42)
*19 (unweighted) exposed infants with missing HIV DNA test results were excluded from this analysis; thus, the total number of HIV-exposed infants differs between tables 1 and 2.
†Adjusted for maternal age, SES, marital status, education, gestational age at first ANC visit (4 week intervals), total number of lifetime pregnancies, whether or not the current
pregnancy was planned and whether or not the infant weighed <2.5 kg at birth.
‡Adjusted for maternal age, SES, marital status, education, gestational age at first ANC visit (4 week intervals), total number of lifetime pregnancies, whether or not the pregnancy was
planned and whether or not the infant weighed <2.5 kg at birth. In this model, missing gestational age was imputed using a Markov chain Monte Carlo multiple imputation algorithm
(see methods).
§See figure 1 for definitions 1a, 1b, 2a, 2b, 3a, 3b.
ANC, antenatal care; ART, antiretroviral therapy; ARV, antiretroviral; ARVP, ARV prophylaxis; PMTCT, preventing mother-to-child transmission; SES, socioeconomic status.
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Building on previous research that used hospital10 37 or
laboratory data38 of known HEI and research that used district-
wide facility-based surveillance among all infants receiving
6-week immunisation,8 12 this study assessed population-level
PMTCT effectiveness at country and provincial levels. Our low
early MTCT of 3.5% is likely to be driven by the high propor-
tion of women receiving ARTor ARVP with low levels of breast
feeding. A previous South African study conducted in 6 (of 12)
districts in one province measured 7.1% (6.2–8.0%) early
MTCT when 13.8% mothers reported being on ART, and
73.8% reported dual therapy.12 The overall early MTCT risk
measured (3.5%) is similar to early MTCT in the long-long arm
reported in Lallemant’s clinical trial (4.1%, 95% CI 1.4 to
6.7%) from Thailand39 where all women received AZT from
28 weeks (10 weeks of maternal AZT), and infants received
6 weeks of ARVs.
Similar to the findings by Stringer et al,13 we show a
population-level MTCT dose–response to the ARV regimen. In
our study, we show that transmission was low and similar in
pregnant women receiving ART (2.1%, 95% CI 1.2% to 3.0%),
ARVP >10 weeks (2.2%, 95% CI 1.2% to 3.1%) or ARVP
≤10 weeks (3.0%, 95% CI 1.9% to 4.0%), and highest among
those receiving incomplete ARVP (8.4%, 95% CI 4.0% to
12.7%) or no ARVs (9.0%, 6.4% to 11.5%). For women receiv-
ing ART, we found higher early MTCT (2.1%) compared with
that measured using routine perinatal surveillance in Canada
(1% overall and 0.4% with >4 weeks ART) where breast
feeding was not recommended.14 Since our study recruited
infants aged 4–8 weeks in June–December 2010, maternal ART
eligibility was confined to CD4 count ≤250 cells/mL or AIDS
stage 4 disease. Limiting our crude analysis to mothers with
reported CD4 results, we observed marginal MTCT differences
if the CD4 result was ≤350 cells/mL or >350 cells/mL (table 2).
As most (>60%) of our pregnant women attended the first
ANC visit after 13 weeks gestation, we postulate a delay in ART
initiation, which may have reduced the population-level impact
of ART. Forbes et al14 show that MTCT among HIV-positive
mothers who receive <4 weeks ARTwas 9%. We postulate that
if appropriate, timely PMTCT interventions were provided,
MTCT in the ART group could have been further reduced,
despite breast feeding (table 3).
To the best of our knowledge, this is the first population-level
countrywide estimate of the effectiveness of a national PMTCT
Table 3 Effect modification of ARV by feeding practice, birth weight, and mode of delivery on the weighted national perinatal MTCT rates,
South Africa, 2010
ARV Other variable Unweighted frequency Weighted MTCT risk estimate% 95% CI
Advanced ARV regimens No breast milk at all 22 2.11 1.28 to 2.95
Exclusive BF 14 3.94 1.98 to 5.90
Mixed BF 7 2.07 0.55 to 3.60
Other ARV regimens No breast milk at all 16 2.57 1.31 to 3.84
Exclusive BF 9 3.42 1.19 to 5.66
Mixed BF 11 4.87 2.01 to 7.74
No ARV No breast milk at all 5 3.45 0.53 to 6.37
Exclusive BF 9 11.50 4.67 to 18.33
Mixed BF 22 11.90 7.45 to 16.35
Advanced ARV regimens Low birth weight 8 2.39 0.54 to 3.54
Normal birth weight 35 2.49 1.78 to 3.33
Other ARV regimens Low birth weight 10 9.28 3.81 to 14.80
Normal birth weight 26 2.32 1.40 to 3.23
No ARV Low birth weight 8 8.37 2.68 to 17.04
Normal birth weight 28 9.15 5.69 to 12.01
Advanced ARV regimens No C-section 34 2.41 1.63 to 3.19
C-section 9 2.72 1.05 to 4.38
Other ARV regimens No C-section 32 3.52 2.31 to 4.72
C-section 4 1.77 0.01 to 3.53
No ARV No C-section 27 7.46 5.00 to 9.93
C-section 9 15.18 6.36 to 23.99
Refer to figure 1 for ARV categories: advance ARV regimens=groups 1a and 1b; other ARV regimens=groups 2a and 2b; no ARV group=group 3a. Note: the missing ARV information
group 3b is excluded from this analysis; Feeding=previous 8 days recall.
ARV, antiretroviral; BF, breast feeding; C-section, caesarean section; MTCT, mother-to-child transmission.
What is already known on this subject
Only six studies on preventing mother-to-child transmission
(MTCT) effectiveness have been conducted in settings larger
than two or three sites. These were surveys in Thailand, the
PEARL study in Zambia, Cote d’Ivoire, Cameroon, South Africa
(two provinces), South Africa (one province—seven sites) and
Canada. The South African study conducted in all primary
healthcare facilities in 6 of 11 health districts of KwaZulu-Natal
province (May 2008–April 2009), South Africa reported a 7.1%
(95% CI 6.2 to 8.0%) risk of HIV transmission at 4–8 weeks,
which was stratified into 7.7% among the 480 mothers who
reported taking an incomplete regimen and 4.9% among the
1912 mothers who reported taking a full regimen. Among the
527 mothers with unreliable antenatal antiretroviral duration,
the frequency of MTCT was 9.9%. The PEARL study reported
10.9% early MTCT. The Canadian study, using routine
surveillance data, reported 5.2% overall MTCT between 1990
and 2010, reducing to 2.9% after 1997. MTCT in mothers on
highly active antiretroviral therapy (HAART) was 1%, and in
mothers who received HAART for more than 4 weeks it was
0.4%. No confidence limits are reported.
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programme using a facility-based approach previously validated
in a high-immunisation coverage and a high-HIV-prevalence
setting.8 12
This survey found large gaps in current systems to eliminate
MTCT—viz. 61%, unplanned pregnancy amongst HEI (table 1),
50% first antenatal clinical attendance >20 weeks gestation (web
appendix table 12) and 85% ARV coverage. Despite these gaps
population level early MTCT of <5% was achieved. This com-
pares with 4–6 week MTCT results modelled on 100% uptake of
WHO Option A in a breastfeeding population.40 Although the
study was conducted 1–8 months after the South African PMTCT
policy changed to WHO Option A, our data show delayed transla-
tion of the new PMTCT policy into practice: 29.4% mothers
reported being on ART, although 62% reported CD4 cell counts
<350 cell/mm3; additionally, only 34%, rather than 100%, of
mothers reported current (6 weeks postdelivery) infant NVP use.
Thus, these results were achieved mainly with the dual therapy
policy adopted in February 2008 (see web appendix 1): we assume
that most mothers would have started ART at CD4 cell count
≤250 cells/mm3 with a recommended regimen of stavudine, lami-
vudine and NVP (switching to efavirenz after the first trimester).41
While this triggers concerns for the time lag between policy adop-
tion and translation into practice, it does convey optimism for
population-level impact of PMTCT programming.
CONCLUSIONS
Country-level success in reducing early MTCT to <5% has
been demonstrated in a high-HIV-prevalence African setting.
Although this is a significant achievement, we postulate that
more early infant HIV infections could have been averted if
pregnancies were planned and adequate antenatal and
PMTCT-related care were accessed earlier. The impact of
PMTCT interventions on long-term infant HIV-free survival, as
well as the population-level impact of various PMTCT regimens
and of WHO PMTCT Option A, needs urgent assessment.
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What this study adds
▸ The South Africa preventing mother-to-child transmission
(PMTCT) Evaluation was a national population-level
evaluation of PMTCT effectiveness conducted at
immunisation services using a probability proportional to
size sampling methodology and weighted analysis to adjust
for sample realisation and population live births. It shows an
86% reduction in vertical transmission of HIV (from 25%
pre-PMTCT interventions to 3.5% in 2010) with
approximately 82 560 early infant HIV infections averted
annually among mothers on predominantly single or dual
therapy antenatal antiretroviral (ARV) prophylaxis or
antiretroviral therapy from CD4 cell count ≤250. The >10
week-long course of azidothymidine regimen and triple ARV
regimen achieved the same level of perinatal effectiveness
( just exceeding 2%). Incomplete ARV prophylaxis or not
receiving ARV drugs with exclusive or mixed breast feeding
was associated with increased perinatal mother-to-child
transmission (MTCT).
▸ The survey provides population-level evidence to
demonstrate the impact of recent investments in PMTCT (to
increase coverage and improve regimens). The survey also
illustrates the utility of national surveys in corroborating
antenatal survey data, tracking MTCT and measuring the
PMTCT cascade, especially the uptake of interventions.
▸ Despite the early population-level PMTCT effectiveness in a
high-HIV-prevalence setting, more data are needed to track
progress, measuring long-term PMTCT effectiveness and
infant HIV-free survival by 24 months postpartum.
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